ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study

C1114

The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES).

2015-12-01

2018-12-08

2023-12-01

Active (not recruiting)

Early phase I

3045

Inclusion Criteria: * Patients received percutaneous coronary intervention with cobalt-chromium everolimus-eluting stent * Patients who are capable of oral dual antiplatelet therapy consisting of asprin and P2Y12 receptor antagonist Exclusion Criteria: * Patients requiring oral anticoagulants * Patients with medical history of intracranial hemorrhage * Patients who have experienced serious complications (myocardial infarction, stroke, and major bleeding) during hospital stay after percutaneous coronary intervention * Patients with drug eluting stents other than Cobalt chromium everolimus eluting stents (Xience) implanted at the time of enrollment * Patients comfirmed to have no tolerability to clopidgorel before enrollment * Patients requiring continuous administration of antiplaelet drugs other than aspirin and P2Y12 receptor antagonists at the time of enrollment * Patients with coronary bioabsorbable vascular scaffolds (BVS) implanted prior to or at the time of enrollment

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 3045, 'type': 'ACTUAL'}}

2023-04-04